- Home
- CBT vs BDTX Comparison
CBT vs BDTX Comparison
Compare CBT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBT
- BDTX
- Stock Information
- Founded
- CBT 2019
- BDTX 2014
- Country
- CBT United States
- BDTX United States
- Employees
- CBT N/A
- BDTX N/A
- Industry
- CBT Major Chemicals
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBT Industrials
- BDTX Health Care
- Exchange
- CBT Nasdaq
- BDTX Nasdaq
- Market Cap
- CBT 4.0B
- BDTX 132.5M
- IPO Year
- CBT N/A
- BDTX 2020
- Fundamental
- Price
- CBT $78.64
- BDTX $2.87
- Analyst Decision
- CBT Hold
- BDTX Strong Buy
- Analyst Count
- CBT 3
- BDTX 6
- Target Price
- CBT $92.67
- BDTX $14.83
- AVG Volume (30 Days)
- CBT 380.5K
- BDTX 1.2M
- Earning Date
- CBT 08-04-2025
- BDTX 08-05-2025
- Dividend Yield
- CBT 2.29%
- BDTX N/A
- EPS Growth
- CBT N/A
- BDTX N/A
- EPS
- CBT 7.72
- BDTX 0.09
- Revenue
- CBT $3,908,000,000.00
- BDTX $70,000,000.00
- Revenue This Year
- CBT N/A
- BDTX N/A
- Revenue Next Year
- CBT $3.55
- BDTX N/A
- P/E Ratio
- CBT $10.16
- BDTX $32.58
- Revenue Growth
- CBT N/A
- BDTX N/A
- 52 Week Low
- CBT $71.64
- BDTX $1.20
- 52 Week High
- CBT $117.46
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- CBT 56.99
- BDTX 68.91
- Support Level
- CBT $76.17
- BDTX $2.43
- Resistance Level
- CBT $79.61
- BDTX $2.72
- Average True Range (ATR)
- CBT 1.75
- BDTX 0.18
- MACD
- CBT 0.35
- BDTX 0.02
- Stochastic Oscillator
- CBT 81.81
- BDTX 99.31
About CBT Cabot Corporation
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.